[1] 贾滨,张楠,石倩,等.北京市朝阳区2009-2013年健康人群流脑带菌状况分析 [J]. 实用预防医学,2016,23(5):614-615. [2] Pelton SI. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines[J]. J Adolesc Health, 2016,59(2 Suppl):S3-S11. [3] Shi F, Zhang A, Zhu B, et al. Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China [J]. Vaccine, 2017,35(18):2343-2350. [4] 国家食品药品监督管理总局.预防用疫苗临床试验不良反应分级标准指导原则[Z]. 2005-10-14. [5] Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2013,62(1):1-28. [6] WHO. Meningococcal vaccines: WHO position paper, November 2011[J]. Wkly Epidemiol Rec, 2011,86(4):521-539. [7] 伍传宏,王跃进,杭纪红,等. A、C、W135、Y 群脑膜炎球菌四价多糖疫苗的安全性和免疫原性研究 [J]. 实用预防医学,2007,14(6):1768-1770. [8] 孟繁岳,庄菱,胡月梅,等. 脑膜炎球菌多糖疫苗安全性及免疫原性评价[J]. 中国公共卫生,2010,26(12):1534-1536. [9] 汤妍,张吉凯,梁剑,等. A、C、Y、W135群脑膜炎球菌多糖疫苗安全性观察[J]. 热带医学杂志,2013,13(7):901-903. [10] 陈万庚,马永法,周爱庆. 国产ACYW135 流脑多糖疫苗免疫安全性观察[J]. 现代预防医学,2011,38(24):5131-5132.